Atezolizumab for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Mar 2023: Trial registered, NCT05770102
  2. 25 Oct 2023: Trial started, NCT05770102

The trials

NCT05770102: DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

State
Under way
Phase
Phase 2 and Phase 3
People
30 planned
Started
25 Oct 2023
Primary completion
Oct 2029
Arms
Treatment Arm 02: Atezolizumab
Results
None posted
  1. 15 Mar 2023: Trial registered
  2. 25 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.